These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2337859)

  • 1. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
    Fosså SD; Gunderson R; Moe B
    Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
    Haarstad H; Jacobsen AB; Schjølseth SA; Risberg T; Fosså SD
    Ann Oncol; 1994 Mar; 5(3):245-8. PubMed ID: 8186172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
    Fosså SD
    Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
    Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
    Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
    Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
    Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
    Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine.
    Massidda B; Migliari R; Padovani A; Scarpa RM; Pellegrini P; Cortesi E; Usai E; Pellegrini A
    J Chemother; 1991 Dec; 3(6):387-9. PubMed ID: 1819623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study.
    Fosså SD; Raabe N; Moe B
    Br J Urol; 1989 Nov; 64(5):468-71. PubMed ID: 2611615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.
    Shinohara N; Kumagai A; Kanagawa K; Maruyama S; Abe T; Sazawa A; Nonomura K
    Jpn J Clin Oncol; 2009 Nov; 39(11):720-6. PubMed ID: 19684042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
    Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
    J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study.
    Fosså SD; Martinelli G; Otto U; Schneider G; Wander H; Oberling F; Bauer HW; Achtnicht U; Holdener EE
    Ann Oncol; 1992 Apr; 3(4):301-5. PubMed ID: 1390305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.
    Porzsolt F; Messerer D; Hautmann R; Gottwald A; Sparwasser H; Stockamp K; Aulitzky W; Moormann JG; Schumacher K; Rasche H
    J Cancer Res Clin Oncol; 1988; 114(1):95-100. PubMed ID: 2965154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.